Dyne Therapeutics’ Post

View organization page for Dyne Therapeutics, graphic

13,890 followers

Dyne partnered with Duchenne muscular dystrophy (#DMD) and myotonic dystrophy type 1 (#DM1) advocates across the globe to inform the design of our clinical trials and to reduce the burdens and inconveniences to trial participants and their families. These findings were published in the journal Research Involvement and Engagement. In honor of #WDAD24 and International #MyotonicDystrophy Awareness Day this month, we're excited to share an insightful conversation from Pat Furlong, founding president and CEO of Parent Project Muscular Dystrophy (PPMD) and Ashish Dugar, PhD, MBA, our Chief Medical Affairs Officer, about this collaboration. Watch the full video: https://bit.ly/3N3brVP and read the paper: https://bit.ly/4dMU8mW #clinicialtrials #patientcenteredresearch

Marissa V.

SVP and Head of Clinical Development Operations

1mo

This is great work and something we should all be striving towards!

Like
Reply
Tammy Burke, EMBA, BSN, RN

Sr. Director, Patient Recruitment, Feasibility & Engagement

1mo

Congratulations! Great work. So happy to follow this!

Like
Reply
Mary-Jean Fanelli, MD, MBA

Strategic Medical Affairs Leader | Driving Medical Transformation | Building & Connecting Teams for Impact and Results | Collaborative Leadership

1mo

Fantastic work with the patient community. Very exciting!

Like
Reply
Laura Genatossio

Senior Vice President, General Manager Sumitomo Pharma Switzerland

1mo

Great conversation!

See more comments

To view or add a comment, sign in

Explore topics